Your browser doesn't support javascript.
loading
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia, Stephen K L; Martin, Miguel; Holmes, Frankie A; Ejlertsen, Bent; Delaloge, Suzette; Moy, Beverly; Iwata, Hiroji; von Minckwitz, Gunter; Mansi, Janine; Barrios, Carlos H; Gnant, Michael; Tomasevic, Zorica; Denduluri, Neelima; Separovic, Robert; Kim, Sung-Bae; Jakobsen, Erik Hugger; Harvey, Vernon; Robert, Nicholas; Smith, John; Harker, Graydon; Zhang, Bo; Eli, Lisa D; Ye, Yining; Lalani, Alshad S; Buyse, Marc; Chan, Arlene.
Afiliação
  • Chia SKL; British Columbia Cancer Agency, University of British Columbia, 600 West 10th Avenue, Vancouver, British Columbia, V5Z4E6, Canada. schia@bccancer.bc.ca.
  • Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain.
  • Holmes FA; Texas Oncology, P.A, Houston, TX, USA.
  • Ejlertsen B; Rigshospitalet, Copenhagen, Denmark.
  • Delaloge S; Institut Gustave Roussy, Villejuif, France.
  • Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
  • von Minckwitz G; Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neu-isenburg, Germany.
  • Mansi J; Biomedical Research Centre, Guy's Hospital, King's College London, London, UK.
  • Barrios CH; Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.
  • Gnant M; Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
  • Tomasevic Z; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
  • Denduluri N; Virginia Cancer Specialists, Arlington, VA, USA.
  • Separovic R; University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.
  • Kim SB; Asan Medical Center, University of Ulsan, Seoul, Korea.
  • Jakobsen EH; Lillebaelt Hospital, Vejle, Denmark.
  • Harvey V; Auckland City Hospital, Grafton, Auckland, New Zealand.
  • Robert N; McKesson Specialty Health and The US Oncology Network, The Woodlands, TX, USA.
  • Smith J; Compass Oncology, Portland, OR, USA.
  • Harker G; Utah Cancer Specialists, Salt Lake City, UT, USA.
  • Zhang B; Puma Biotechnology, Inc., Los Angeles, CA, USA.
  • Eli LD; Puma Biotechnology, Inc., Los Angeles, CA, USA.
  • Ye Y; Puma Biotechnology, Inc., Los Angeles, CA, USA.
  • Lalani AS; Puma Biotechnology, Inc., Los Angeles, CA, USA.
  • Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Chan A; Breast Cancer Research Centre-WA, Perth & Curtin University, Nedlands, Australia.
Breast Cancer Res ; 21(1): 39, 2019 03 11.
Article em En | MEDLINE | ID: mdl-30867034
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias da Mama / Biomarcadores Tumorais / Classe I de Fosfatidilinositol 3-Quinases / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias da Mama / Biomarcadores Tumorais / Classe I de Fosfatidilinositol 3-Quinases / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article